Q2 2025 13F Holders as of 6/30/2025
-
Type / Class
-
Equity / Common Stock, $0.001 par value
-
Shares outstanding
-
120M
-
Number of holders
-
115
-
Total 13F shares, excl. options
-
47.6M
-
Shares change
-
+3.76M
-
Total reported value, excl. options
-
$158M
-
Value change
-
+$12.7M
-
Put/Call ratio
-
3.17
-
Number of buys
-
66
-
Number of sells
-
-45
-
Price
-
$3.31
Significant Holders of Aquestive Therapeutics, Inc. - Common Stock, $0.001 par value (AQST) as of Q2 2025
138 filings reported holding AQST - Aquestive Therapeutics, Inc. - Common Stock, $0.001 par value as of Q2 2025.
Aquestive Therapeutics, Inc. - Common Stock, $0.001 par value (AQST) has 115 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 47.6M shares
of 120M outstanding shares and own 39.6% of the company stock.
Largest 10 shareholders include Bratton Capital Management, L.P. (9.81M shares), BlackRock, Inc. (6.48M shares), VANGUARD GROUP INC (4.33M shares), MILLENNIUM MANAGEMENT LLC (2.98M shares), PERCEPTIVE ADVISORS LLC (2.19M shares), GEODE CAPITAL MANAGEMENT, LLC (1.98M shares), Pale Fire Capital SE (1.68M shares), STATE STREET CORP (1.51M shares), MORGAN STANLEY (1.41M shares), and BANK OF AMERICA CORP /DE/ (1.28M shares).
This table shows the top 115 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.